USMLE

Cetuximab, Panitumumab

4,605 views
Oncology Pharm
  1. Bleomycin
  2. Dactinomycin, Actinomycin D
  3. Doxorubicin, Daunorubicin
  4. Azathioprine, 6-MP
  5. Cladribine
  6. Cytarabine
  7. Busulfan
  8. Cyclophosphamide, Ifosfamide
  9. Nitrosoureas
  10. Paclitaxel
  11. Vincristine, Vinblastine
  12. Cisplatin, Carboplatin, Oxaliplatin
  13. Etoposide, Teniposide
  14. Irinotecan, Topotecan
  15. Bevacizumab
  16. Erlotinib
  17. Cetuximab, Panitumumab
  18. Imatinib, Dasatinib
  19. Rituximab
  20. Bortezomib, Carfilzomib
  21. Trastuzumab
  22. Dabrafenib, Vemurafenib
  23. Raloxifene and Tamoxifen
  24. Hydroxyurea
  25. Procarbazine

Summary

Cetuximab and panitumumab are monoclonal antibodies against EGFR and are used to treat stage IV colorectal cancer and head and neck cancers. Patients on cetuximab and panitumumab may experience elevated LFTs, rash, and diarrhea as side effects. 

Key Points

  • Cetuximab / Panitumumab
    • Mechanism
      • Monoclonal antibody against EGFR
    • Clinical use
      • Stage IV colorectal cancer
        • Wild-type KRAS
      • Head and neck cancers
    • Adverse effects
      • Elevated LFTs
      • Rash
      • Diarrhea